改良DT-Vel与标准DT-Vel方案治疗多发性骨髓瘤的疗效比较

Comparison of efficacy and safety between modified DT-Vel and standard DT-Vel regimen in the treatment of multiple myeloma

目的:评估两种硼替佐米方案治疗多发性骨髓瘤(MM)的疗效及安全性。方法:34例MM患者采用改良及标准DT-Vel方法。结果:16例改良DT-Vel方案的患者,4例CR,5例PR,3例VGPR,2例MR,2例未评价,ORR为75.0%。相较18例标准DT-Vel方案患者4例CR,6例PR,4例VGPR,4例MR,ORR为77.8%,无统计学差异。结论:改良DT-Vel方案与标准DT-Vel方案疗效相当,患者耐受性好,是一种值得推荐的治疗MM安全、有效的方法。

Objective： To evaluate the curative effect of Bortezomib in treatment of newly diagnosed multiple myeloma. Methods： Thirty- four patients with newly diagnosed multiple myeloma received improved and the standard DT- Vel chemotherapy regimen. Results： In improved DT- Vel,4 patients complete remission,5 patients were partial remission,3 patients very good partial remission,2 mild remission,2 patients were not evaluated. overall response rate was 75. 0%. In standard DT- Vel 4 complete remission,6 partial remission,4 very good partial remission,4 mild remission,overall response rate was 77. 8%. Conclusion： Improved DT- Vel is well tolerated and effective in treatment of newly diagnosed multiple myeloma.